Aurobindo Pharma may test Rs 780: Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "In terms of valuations, Aurobindo Pharma is cheaper. It is 15 times FY17. If you look at the valuation in terms price to earnings ratio (P/E) Lupin would be slightly more expensive. If you look at price targets and ranges, I would say Aurobindo in the next six months can touch Rs 780. I would put a stoploss of Rs 675."She further added, "In Lupin, it is very hard to give a stoploss because there are a lot of negative news flows. And it is like catching a falling knife. At the same time, just to put my neck out, I would say Rs 1,660. If it goes below that, I would suggest to books out and on the upside, definitely, one will really need to wait and watch what the news flows are to understand, what the impact would be on the US business."